Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 12/2002

01-12-2002 | Leading Article

Defining the Role of the Caregiver in Alzheimer’s Disease Treatment

Authors: Professor Henry Brodaty, Alisa Green

Published in: Drugs & Aging | Issue 12/2002

Login to get access

Abstract

The day-to-day responsibility of caring for a person with dementia often exacts a toll upon the caregiver, which may be manifested psychologically, physically, socially and financially.
The last decade has witnessed the advent of drug availability for the treatment of Alzheimer’s disease, specifically the cholinesterase inhibitors. Caregivers are integral to the initiation, administration and monitoring of treatment. In particular, they provide substitute informed consent when patients are no longer competent to do so. While there is evidence that cholinesterase inhibitors may reduce caregiver burden and time spent assisting patients, there are also burdens associated with being the person responsible for administering medication.
Caregivers are key to research into the use of medications for Alzheimer’s disease. They have roles in recruitment and consent and monitoring response and adverse effects. Increasingly, caregivers themselves are recognised as legitimate targets for evaluating the efficacy of new pharmacological agents for Alzheimer’s disease (as benefits have been demonstrated for them).
Caregivers have responsibilities regarding the drug treatment of patients with Alzheimer’s disease, and require information about the medications so that they can have realistic expectations. Doctors need to work in partnership with care-givers and patients when prescribing drugs for Alzheimer’s disease.
Literature
1.
2.
3.
Brodaty H, Hadzi-Pavlovic D. Psychosocial effects on care-givers of living with persons with dementia. Aust N Z J Psychiatry 1990; 24: 351–61PubMedCrossRef
4.
Baumgarten M, Battista RN, Infante-Rivard C, et al. The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol 1992; 45(1): 61–70PubMedCrossRef
5.
Grafström M, Winblad B. Family burden in the care of the demented and nondemented elderly — a longitudinal study. Alzheimer Dis Assoc Disord 1995; 9(2): 78–86PubMedCrossRef
6.
Gonzalez-Salvador MT, Arango C, Lyketsos CG, et al. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999; 14(9): 701–10PubMedCrossRef
7.
Wright LK, Hickey JV, Buckwalter KC, et al. Emotional and physical health of spouse caregivers of persons with Alzheimer’s disease and stroke. J Adv Nurs 1999; 30: 552–63PubMedCrossRef
8.
Stephens MA, Ogrocki PK, Kinney JM. Sources of stress for family caregivers of institutionalized patients. J Appl Gerontol 1991; 10(3): 328–42PubMedCrossRef
9.
Schulz R, Vistainer P, Williamson GM. Psychiatric and physical morbidity effects of caregiving. J Gerontol 1990; 45: P181–91PubMedCrossRef
10.
Haley WE, Levine EG, Brown SL, et al. Stress, appraisal, coping and social support as predictors of adaptational outcome among dementia caregivers. Psychol Aging 1987; 2: 323–30PubMedCrossRef
11.
Schulz R, Williamson GM. The measurement of caregiver outcomes in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11(6): 117–24PubMed
12.
Brodaty H. The family and drug treatments for Alzheimer’s disease. In: Gauthier S, editor. Pharmacotherapy of Alzheimer’s disease. London: Martin Dunitz, 1998: 123–39
13.
Braekhus A, Oksengard AR, Engedal K, et al. Social and depressive stress suffered by spouses of patients with mild dementia. Scand J Prim Health Care 1998; 16: 242–6PubMed
14.
Max W. Cost of illness of dementia. In: Health economics of dementia. Chichester: Wiley, 1998: 197–206
15.
Leon J, Neumann PJ, Hermann RC, et al. Health-related quality-of-life and service utilization in Alzheimer’s disease: a cross sectional study. Am J Alzheimers Dis 2000; 15(2): 94–108CrossRef
16.
Max W, Webber PA, Fox PJ. Alzheimer’s disease: the unpaid burden of caring. J Aging Health 1995; 7: 179–99PubMedCrossRef
17.
Mace NK, Rabins PV. The 36-hour day. Baltimore (MD): Johns Hopkins University Press, 1991
18.
Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16: 770–8PubMedCrossRef
19.
Brodaty H, McGilchrist C, Harris L, et al. Time until institutionalization and death in patients with dementia: role of care-giver training and risk factors. Arch Neurol 1993; 50: 643–50PubMedCrossRef
20.
Morycz RK. Caregiving strain and the desire to institutionalise family members with Alzheimer’s disease. Res Aging 1985; 7: 329–61PubMedCrossRef
21.
Annerstedt L, Elmstahl S, Ingvad B, et al. Family caregiving in dementia — an analysis of the caregiver’s burden and the “breaking-point” when home care becomes inadequate. Scand J Public Health 2000; 28: 23–31PubMed
22.
Waite LM, Broe GA, Grayson DA, et al. The incidence of dementia in an Australian community population: the Sydney Older Persons Study. Int J Geriatr Psychiatry 2001; 16: 680–9PubMedCrossRef
23.
Alafuzoff, I Soininen, H. Neuropathology and ethiopathogenesis of Alzheimer’s disease. In: Qizilbash N, Schneider L, Chui H, et al., editors. Evidence-based dementia practice. Oxford: Blackwell, 2002: 244–59
24.
Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137–47PubMedCrossRef
25.
Cummings J. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4–15PubMed
26.
Qizilbash N, Birks J, Lopez Arrieta J, et al. Tacrine for Alzheimer’s disease (Cochrane Review). Available in the Cochr-ane Library. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2001
27.
Winblad B, Engedal MD, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–95PubMedCrossRef
28.
Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45PubMedCrossRef
29.
Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44PubMedCrossRef
30.
Mohs R, Doody R, Morris JL, et al. Donepezil preserves functional status in Alzheimer’s disease patients: results from a 1-year prospective placebo-controlled study. Eur Neuro-psychopharmacol 1999; 9 Suppl. 5: S328CrossRef
31.
Doody RS. Clinical profile of donepezil in the treatment of Alzheimer’s disease. Gerontology 1999; 45 Suppl. 1: 23–32PubMedCrossRef
32.
Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20PubMedCrossRef
33.
Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000; 44: 236–41PubMedCrossRef
34.
Birks JS, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease (Cochrane review). Available in the Cochrane Library. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001
35.
McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000; 15: 387–92PubMedCrossRef
36.
Olin J, Schneider L. Systematic review of galantamine for Alzheimer’s disease (Cochrane review). Available in the Cochrane Library. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001
37.
Zajaczkowski W, Quack G, Danysz W. Infusion of (+)-MK-801 and metamine — contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296: 239–46PubMedCrossRef
38.
Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best study. Int J Geriatr Psychiatry 1999; 14(2): 135–46PubMedCrossRef
39.
Reisberg B, Windscheif U, Ferris SH, et al. Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial [abstract]. Neurobiol Aging 2000; 21(1S): S275CrossRef
40.
Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–9PubMedCrossRef
41.
Wilcock G, for the MMM 500 trial group. Cognitive improvement my memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 trial) [online]. Poster presented at the 6th International Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5–8; Stockholm, Sweden. Available at URL: http://​www.​memant-ine.​com/​inhalte/​s1.​html
42.
Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, editor. Handbook of dementing illnesses. New York: Marcel Dekker, 1994: 461–75
43.
Peisah C, Brodaty H. Pharmacological management of challenging behaviours in people with dementia. Geriatric Therapeutics 1997; 27(1): 49–57
44.
Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer’s disease. Int Psychogeriatr 2000; 12(3): 389–401PubMedCrossRef
45.
Shikiar R, Shakespeare A, Sagnier P-P, et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer’s disease: results from the MALT clinical trial. J Am Geriatr Soc 2000; 48: 268–74PubMed
46.
Tariot PN, Truyen L. Galantamine reduces the distress of caregivers of Alzheiimer’s disease patients [abstract]. Proceedings of the 10th Congress of the International Psycho-geriatrics Association (IPA); 2001 Sep 9–14; Nice, France. Int Psychogeriatr 2001; 13(S2): P348
47.
Mastey V, Wimo A, Winblad B, et al. Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer’s disease [abstract]. J Am Geriatr Soc 2001; 49(4): S20
48.
Lilienfeld S, Gaens E. Galantamine alleviates caregiver burden in Alzheimer’s disease: a 12 month study. Poster presented at the 5th Congress of the European Federation of Neurological Societies; 2000 Oct 14–18: Copenhagen, Denmark. Eur J Neurol 2000; 7 (Suppl. 3): P3111
49.
Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer’s disease. Clin Pharmacol Ther 1995; 58(2): 228–36PubMedCrossRef
50.
Hinchliffe A, Katona C, Livingstone G. The assessment and management of behavioural manifestations of dementia: a review and results of a controlled trial. International Journal of Psychiatry in Clinical Practice 1997; 1(13): 157–68CrossRef
51.
Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 1996; 47(1): 166–77PubMedCrossRef
52.
McRae T, Knopman D, Duttagupta S, et al. Donepezil delays time to nursing home placement [abstract]. J Am Geriatr Soc 2001; 49(4): S132
53.
Brodaty H, Grossman F, Bruynseels J, et al. Risperidone in the treatment of agitation and psychosis of dementia. Proceedings of the 10th Congress of the International Psychogeriatrics Association; 2001 Sep 9–14: Nice, France. Int Psychogeriatr 2001; 13(S2): S108
54.
Ranelli PL, Aversa SL. Medication-related stressors among family caregivers. Am J Hosp Pharm 1994; 51(1): 75–9PubMed
55.
Green A, Brodaty H. Care-giver interventions. In: Qizilbash N, Schneider L, Chui H, et al., editors. Evidence-based dementia practice. Oxford: Blackwell Publishing, 2002: 764–94
56.
Brodaty H, Green A, Koschera A. Evidence bases for interventions for caregivers of people with dementia [abstract]. J Neurol Sci 2001; 187 Suppl. 1: S118
57.
Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology 2001; 20(2): 51–6PubMedCrossRef
58.
Bent S, Saint S, Vittinghoff E, et al. Antibiotics in acute bronchitis: a meta-analysis. Am J Med 1999; 107(1): 62–7PubMedCrossRef
59.
Brodaty H, Gresham M. Effect of a training programme to reduce stress in caregivers of patients with dementia. BMJ 1989; 299: 1375–9PubMedCrossRef
60.
Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital Dementia Caregivers’ Training Programme. Int J Geriatr Psychiatry 1997; 12: 183–92PubMedCrossRef
61.
Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalisation of Alzheimer’s disease patients: treatment of spouse-caregivers. Gerontologist 1993; 33(6): 730–40PubMedCrossRef
62.
Mittelman MS, Ferris SH, Shulman E, et al. A comprehensive support group program: effect on depression in spouse-caregivers of AD patients. Gerontologist 1995; 35: 792–802PubMedCrossRef
63.
Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placements of patients with Alzheimer’s disease: a randomized controlled trial. JAMA 1996; 276(21): 1725–31PubMedCrossRef
64.
Mittelman MS, Brodaty H, Burns A. A multinational clinical trial of the effectiveness of a combined psychosocial and pharmacological intervention for AD patients and family caregivers. Proceedings of the World Alzheimer Congress; 2000 July 9–13; Washington (DC)
Metadata
Title
Defining the Role of the Caregiver in Alzheimer’s Disease Treatment
Authors
Professor Henry Brodaty
Alisa Green
Publication date
01-12-2002
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 12/2002
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200219120-00001

Other articles of this Issue 12/2002

Drugs & Aging 12/2002 Go to the issue

Therapy In Practice

Background to and Management of Treatment-Related Bone Loss in Prostate Cancer

Therapy In Practice

Treatment of Acid-Related Diseases in the Elderly with Emphasis on the Use of Proton Pump Inhibitors

Review Article

Management Strategies for the Treatment of Neuropathic Pain in the Elderly

Original Research Article

Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits